Gene mutations in NSCLC: Types, risk factors, and more

Non-small cell lung cancer (NSCLC) is not one diseaseit’s a whole neighborhood. And the “street address” that helps doctors pick the best treatment is
often written in your tumor’s DNA.

That’s where gene mutations (and related changes like gene fusions) come in. Some alterations act like a stuck gas pedal for cancer growth. Others are
more like a broken brake line. Either way, modern NSCLC care increasingly depends on biomarker testing to identify what’s driving a
person’s cancerbecause a treatment that works brilliantly for one mutation can be a total no-show for another.

Below is a clear, in-depth guide to the most common NSCLC gene mutations, what raises risk, how testing works, and why the results can change the entire
treatment plan. (And yes, we’ll decode the alphabet soup without making you feel like you missed a semester of Molecular Biology 101.)

First, what “gene mutations” means in NSCLC

A gene mutation is a change in DNA. In NSCLC, most mutations are somatic, meaning they happen during a person’s life
and are found in the cancer cellsnot in every cell of the body. That’s why most people with NSCLC don’t “inherit” the tumor mutation from a parent.

Some changes are drivers (they help the cancer start or grow). Others are passengers (they’re along for the ride).
When doctors talk about “actionable” mutations, they mean changes with a treatment that specifically targets that alterationor one that strongly guides
therapy choices.

Types of gene alterations that matter most in NSCLC

NSCLC biomarker results usually fall into a few categories:

• Point mutations (single-letter DNA changes), like KRAS G12C or EGFR L858R
• Insertions/deletions (extra or missing DNA), like EGFR exon 19 deletions or EGFR exon 20 insertions
• Gene fusions/rearrangements (two genes abnormally joined), like ALK, ROS1, RET, or NTRK fusions
• Skipping events (RNA splicing changes), like MET exon 14 skipping
• Amplifications (extra gene copies), sometimes seen with MET or HER2

The headline NSCLC mutations and fusions (and why they matter)

The list below focuses on alterations commonly tested in advanced NSCLC (especially adenocarcinoma) and frequently tied to targeted therapies.
Availability of specific drugs can depend on stage, prior treatments, and local approvals, so treat this as a roadmapnot a prescription.

EGFR (epidermal growth factor receptor)

What it is: EGFR mutations can keep growth signals permanently “on.” Two classic EGFR mutationsexon 19 deletions and
exon 21 L858Rare among the most important drivers in NSCLC.

Why it matters: EGFR-positive NSCLC often responds well to EGFR-targeted therapy. In the U.S., common approaches include EGFR inhibitors
and newer combinations for certain first-line settings. Some EGFR mutations also show up after resistance develops, which is why repeat testing can be so
valuable.

A newer twist: EGFR exon 20 insertions are a different beasthistorically harder to target. In the U.S., amivantamab
has been approved for EGFR exon 20 insertion–mutated NSCLC after platinum therapy, and EGFR exon 19/L858R first-line options expanded with a lazertinib +
amivantamab combination approval.

ALK rearrangements (ALK fusions)

What it is: ALK fusions create an abnormal ALK signaling protein that drives cancer growth.

Who it often shows up in: More commonly in adenocarcinoma and in people who have never smoked or smoked lightly (but it can occur in any
patient).

Why it matters: ALK-targeted therapies can be highly effective, often with meaningful disease control and improved quality of life
compared with older approaches.

KRAS (including KRAS G12C)

What it is: KRAS mutations are among the most common in NSCLC. A specific subtype, KRAS G12C, has targeted treatments.

Risk pattern: KRAS mutations are more frequently associated with smoking-related lung cancers, though they can occur in anyone.

Why it matters: Two KRAS G12C inhibitorssotorasib and adagrasibhave FDA accelerated approvals for
previously treated KRAS G12C-mutated advanced NSCLC, which made “undruggable KRAS” a phrase we now say mostly for historical comedy.

ROS1 fusions

What it is: ROS1 fusions produce an abnormal kinase signal that can drive tumor growth.

Why it matters: ROS1-positive NSCLC can respond well to targeted therapy (commonly using ROS1 inhibitors), which can significantly change
first-line and later-line planning.

BRAF (especially BRAF V600E)

What it is: BRAF mutations affect a growth-signaling pathway. The best-known actionable mutation is BRAF V600E.

Why it matters: BRAF V600E–positive NSCLC may be treated with a BRAF/MEK-targeted strategy, often changing the chemo-versus-targeted
conversation immediately.

MET (MET exon 14 skipping and MET amplification)

What it is: MET exon 14 skipping prevents normal “cleanup” of MET signaling, allowing it to stay active longer. MET amplification can
also boost growth signals.

Why it matters: MET exon 14 skipping is considered actionable in advanced disease, with MET-targeted drugs used in appropriate settings.
It can also show up as a resistance mechanism after other targeted therapies, which is why re-testing can matter.

RET fusions

What it is: RET fusions can drive tumor growth, typically in adenocarcinoma.

Why it matters: RET inhibitors (for example, selpercatinib) have FDA approval for RET fusion–positive metastatic NSCLC, offering a
focused option that can outperform “one-size-fits-all” treatment plans for many patients.

NTRK fusions

What it is: NTRK gene fusions are rare in NSCLC but important because they can be treated with “tumor-agnostic” TRK inhibitorsmeaning
the drug is approved based on the mutation, not the cancer’s location.

HER2 (ERBB2) mutations

What it is: HER2 (also called ERBB2) mutations can drive NSCLC growth. This is different from HER2 overexpression in breast cancersame
family name, different plot twist.

Why it matters: The FDA granted accelerated approval to fam-trastuzumab deruxtecan (Enhertu) for unresectable or
metastatic NSCLC with activating HER2 mutations after prior systemic therapyan important option for a subset of patients.

“Not always targetable, but still important” genes

Some genes don’t (yet) have a direct “this pill targets that mutation” match, but they still matter because they can influence prognosis, resistance, or
treatment response. Examples often discussed in NSCLC include TP53, STK11, KEAP1, and
SMARCA4.

Think of these as the supporting cast that sometimes steals the showespecially when treatment decisions involve immunotherapy, clinical trials, or
understanding why a tumor is behaving aggressively.

Risk factors: what increases the chance of NSCLC (and the mutations behind it)

There are two related questions people often mean by “risk factors”:
(1) what raises the risk of developing NSCLC, and (2) what influences which mutations are more likely once NSCLC
occurs.

Major NSCLC risk factors (the big ones)

• Smoking: Cigarette smoking is the leading risk factor for lung cancer, and in the U.S. it’s linked to a large majority of lung cancer
  deaths.
• Radon: Radon exposure is a major cause of lung cancer in the U.S. and is especially significant for people who don’t smoke. Risk is
  higher when smoking and radon exposure combine (a not-fun “team-up episode”).
• Secondhand smoke
• Occupational exposures: asbestos, diesel exhaust, and certain industrial chemicals
• Air pollution (especially long-term exposure)
• Prior radiation to the chest (in some situations)
• Family history/genetics (usually smaller effect than smoking, but still relevant)

How risk factors connect to mutation patterns

Many carcinogens (like tobacco smoke) damage DNA. More damage can mean more mutations across the tumor genomeoften called a higher “mutational burden.”
In very broad terms:

• Smoking-associated cancers tend to have more mutations overall, and certain mutation patterns are more common (including some KRAS and
  TP53 changes).
• Never-smokers with NSCLC often have fewer total mutations, but a higher chance of having a single strong driver alteration (like EGFR
  mutations or ALK/ROS1/RET fusions), which can be especially actionable.

Important caveat: these are population-level trends. Individual patients can land anywhere on the spectrum, which is exactly why testing matters.

How doctors find mutations: biomarker testing (tissue and blood)

Biomarker testing looks for genetic or protein changes in a tumor. For advanced NSCLC, many guidelines and expert groups support broad molecular testing
because it can identify multiple actionable targets at once.

Tissue testing (biopsy-based testing)

Tumor tissue is often considered the gold standard, because it provides direct tumor material for analysis. Testing methods can include:

• Next-generation sequencing (NGS): checks many genes at once (efficient when tissue is limited)
• Immunohistochemistry (IHC): detects protein changes (often used for ALK, ROS1 screening, and PD-L1)
• FISH/PCR: more targeted methods for specific alterations

Liquid biopsy (blood-based testing)

A liquid biopsy typically looks for circulating tumor DNA (ctDNA) in the blood. It can be extremely useful when:

• there isn’t enough tissue for full testing,
• a biopsy would be risky or delayed,
• you need to check for resistance mutations over time.

But liquid biopsy can miss mutations if the tumor isn’t shedding enough DNA into the blood. So a negative liquid biopsy doesn’t always mean “no mutation.”
It can mean “not detected in bloodtry tissue if possible.”

In the U.S., the NCI notes FDA-approved liquid biopsy tests used as companion diagnostics include Guardant360 CDx and
FoundationOne Liquid CDx.

Practical testing tips patients actually use

• Ask what genes were tested (don’t accept “we did some testing” as a complete sentence).
• Ask if it was broad NGS or just a few single-gene tests.
• Request a copy of the reportit helps with second opinions and clinical trial searches.
• If results are negative or incomplete, ask whether tissue was limited and if liquid biopsy or repeat sampling makes sense.

Why mutation results can change treatment (sometimes dramatically)

In advanced NSCLC, identifying an actionable driver mutation often shifts first-line or next-line therapy toward targeted treatments. Targeted therapies
are designed to hit the specific growth pathway the tumor relies onoften with a different side-effect profile than chemotherapy.

Examples of how results steer therapy

• EGFR exon 19 deletion or L858R: EGFR-targeted therapy is a cornerstone; FDA-approved first-line options include lazertinib +
  amivantamab for these mutations.
• EGFR exon 20 insertion after platinum therapy: amivantamab has traditional approval for this setting.
• KRAS G12C after prior therapy: sotorasib or adagrasib may be considered in appropriate patients.
• RET fusion: selpercatinib is an FDA-approved targeted therapy option.
• HER2 (ERBB2) activating mutation after prior therapy: fam-trastuzumab deruxtecan (Enhertu) is FDA accelerated-approved.
• Earlier-stage note: some targeted therapy can be used after surgery in selected cases (for example, adjuvant osimertinib for certain
  EGFR-mutant early-stage NSCLC).

Also important: what happens when tumors evolve

Tumors can develop resistance over timemeaning the cancer changes in a way that helps it dodge the drug. That’s why oncologists sometimes order
re-testing (often via liquid biopsy or a new tissue biopsy) at progression to look for new targets or resistance mechanisms.

And because medicine moves fast, approvals can change: for example, the FDA listed the withdrawal of the accelerated approval indication for
mobocertinib (Exkivity) for EGFR exon 20 insertion NSCLC.

What if no actionable mutation is found?

If broad testing doesn’t reveal an actionable driver, treatment decisions often lean more on:

• PD-L1 expression (a protein marker often used to guide immunotherapy choices)
• overall health and comorbidities
• tumor histology (adenocarcinoma vs squamous, etc.)
• clinical trial options, especially if the tumor has rare or emerging alterations

This is not “bad news,” but it can be “less specific news.” The upside: immunotherapy and chemo-immunotherapy options can still be very effective for
many patients without classic driver mutations.

FAQ: quick answers people want immediately

Are NSCLC mutations inherited?

Most NSCLC driver mutations are somatic (acquired), not inherited. However, if there’s strong family history or unusual cancer patterns,
clinicians may consider germline genetic counseling/testing as a separate step.

Can my mutation change over time?

Yes. Under treatment pressure, tumors can evolve. That’s why re-biopsy or liquid biopsy is sometimes recommended when the cancer progresses.

How long does biomarker testing take?

Turnaround time varies by lab and method. Broad NGS can take longer than single-gene tests, but it often prevents delays later because it answers many
questions at once.

Should every NSCLC patient get mutation testing?

Testing is especially emphasized for advanced/metastatic NSCLC and commonly for adenocarcinoma, but many experts support broad testing
for advanced NSCLC more generallyparticularly in never-smokers or when clinical features suggest a driver mutation may be present.

Real-world experiences: what this journey often feels like (and what helps)

Let’s talk about the part people rarely put on a lab report: the experience of living through “molecular testing season,” starring you, your care team,
and a supporting cast of acronyms.

1) The waiting game is real. Many patients describe biomarker testing as a strange limbo: you have a diagnosis, but you don’t have the
“full story” yet. It can feel backward to wait for results before starting treatmentespecially when your instincts scream, “Do something today.”
Clinicians often balance urgency with accuracy, because starting the wrong therapy can mean missing the chance to use a targeted drug that fits your
tumor’s biology.

What helps: asking your team what’s being tested, what the expected timeline is, and whether a liquid biopsy could speed up early
decision-making while tissue testing is pending.

2) The alphabet soup can be emotionally loud. Patients often say the mutation name becomes “the new identity label,” even though it’s
really just a tool for choosing treatment. “I’m EGFR-positive” or “I’m ALK+” can feel both empowering (clear direction!) and scary (now I have a new
lifelong vocabulary word).

What helps: reframing the mutation as actionable informationyour tumor handed you a clue. You didn’t “cause” the mutation, and you
don’t need to earn a graduate degree to understand your options. A simple question like “What does this mutation change about my treatment choices?”
can cut through the noise.

3) People often become their own project manager. In real life, getting comprehensive testing can involve coordinating pathology
samples, insurance approvals, and referrals. Many caregivers describe tracking this like a high-stakes shipping package: “Where’s the tissue? Who has the
report? When does it arrive?”

What helps: requesting a copy of the biomarker report, keeping a single folder (digital or paper), and asking if your center routinely
uses broad NGS panels. Patient advocacy organizations often provide checklists and plain-language guides that make the system easier to navigate.

4) Side effects are differentsometimes gentler, sometimes just… different. People on targeted therapy often report that the experience
doesn’t feel like traditional chemo, but it isn’t “side-effect-free.” EGFR-targeted drugs can be associated with skin and nail changes; other targeted
treatments can cause fatigue, GI issues, swelling, or lab changes. Patients frequently say the biggest improvement came not from “toughing it out,” but
from early side-effect management: reporting symptoms quickly, adjusting supportive meds, and collaborating on dose changes when appropriate.

5) The most common emotional whiplash: hope + uncertainty. Targeted therapy success stories are real, and they can bring genuine relief.
At the same time, many patients live with the knowledge that resistance can emerge. That can feel like celebrating a win while hearing distant thunder.

What helps: focusing on controllablesstaying on schedule with scans, discussing what “next steps” could look like if the cancer changes,
and asking about clinical trials early (not only as a last resort). Many patients also find it grounding to connect with others who share the same
mutation subtype, because the lived experience can be surprisingly specific.

If you take one thing from this section, let it be this: biomarker testing isn’t just a technical step. It’s a decision-making tool that can buy time,
widen options, and help your care team tailor treatment to your NSCLCnot an average-of-everyone NSCLC.

Conclusion

Gene mutations in NSCLC aren’t just scientific triviathey’re often the difference between “standard treatment” and a plan tailored to your tumor’s
specific wiring. The major actionable drivers (EGFR, ALK, KRAS G12C, ROS1, BRAF V600E, MET exon 14 skipping, RET, NTRK, HER2/ERBB2, and others) can
guide targeted therapy choices, influence outcomes, and inform what to do when the cancer evolves.

The most practical takeaway: ask for comprehensive biomarker testing, understand what was tested, and keep a copy of the report. In a
field where new approvals and strategies appear regularly, having the right mutation information is like having the right mapwithout it, you can still
travel, but you might miss the best routes.